Crisis lines testing AI to help review response

By |2023-06-22T09:46:04-07:00June 22nd, 2023|Brief Bulletins from the Field, We Know Psychiatry|

Crisis support lines are currently undergoing testing of artificial intelligence (AI) to assess the quality of their response. These support lines rely on well-trained counselors who are adept at handling sensitive conversations, particularly those involving potential suicide. However, the process of reviewing randomly selected recordings to ensure quality control is [...]

New APA Study Shows a Spike in Anxiety Among a Large Swath of America

By |2023-05-10T14:11:20-07:00May 10th, 2023|Brief Bulletins from the Field, We Know Psychiatry|

According to the American Psychiatric Association's annual poll, 70% of adults in the United States report feeling anxious or extremely anxious about their own and their family's safety. This number is 6% higher than in the past two years, although lower than during the early stages of the pandemic in [...]

Neuromodulation Device for Depression Granted Designation from FDA

By |2023-03-16T13:04:04-07:00March 16th, 2023|Brief Bulletins from the Field, We Know Psychiatry|

According to published reports, The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Sooma Medical's portable, noninvasive neuromodulation device for treating depression, which can be administered by the patient. The device, which uses transcranial direct current stimulation to target specific areas of the brain and alleviate [...]

Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression

By |2023-02-08T08:34:35-08:00February 8th, 2023|Brief Bulletins from the Field, We Know Psychiatry|

Objective: To compare the efficacy and speed of achieving remission/response in treatment-resistant depression (TRD) patients treated with subanesthetic intravenous (IV) ketamine and intranasal (IN) esketamine approved by the US Food and Drug Administration (FDA). Methods: The study was observational and included 62 adults with TRD who received up to 6 [...]

FDA Approves Second Anti-Amyloid for Alzheimer’s Disease

By |2023-01-13T12:24:03-08:00January 13th, 2023|Brief Bulletins from the Field, We Know Psychiatry|

The US Food and Drug Administration (FDA) has approved the anti-amyloid beta protofibril antibody lecanemab (Leqembi, Eisai) for the treatment of early Alzheimer's disease (AD). The agency approved the treatment on the basis of findings from the CLARITY AD trial, which showed modest cognitive benefit for patients with early AD [...]

Study finds association between sleep duration and multimorbidity

By |2022-11-01T11:56:08-07:00November 1st, 2022|Brief Bulletins from the Field, We Know Psychiatry|

In a study published in PLOS Medicine that uses data spanning 25 years, the authors observed short sleep duration to be associated with risk of chronic disease and subsequent multimorbidity but not with progression to death. There was no robust evidence of an increased risk of chronic disease among those [...]

First of its kind drug, to reverse effects of cocaine intoxication, awarded grant

By |2022-08-05T08:31:56-07:00August 5th, 2022|Brief Bulletins from the Field, We Know Psychiatry|

An enzyme that efficiently degrades and metabolizes cocaine has been given a ‘cooperative agreement grant’ from the National Institute on Drug Abuse (NIDA) part of the National Institutes of Health. The recombinant enzyme is a double-mutant cocaine esterase 200 mg intravenous (IV) solution and treats cocaine intoxication, which refers to the state [...]

Mechanisms and Necessity of Psychedelic ‘Tripping’

By |2022-07-28T10:20:17-07:00July 28th, 2022|Brief Bulletins from the Field, We Know Psychiatry|

It is known that psychedelics activate serotonin 2A receptors, which eventually leads to states like increased empathy and out-of-body experiences. One of the key questions remaining n psychedelic medicine is quantifying how this class of drugs operates at the higher-order brain level. As reported in Psychiatric News, part of a [...]

News Snippet: School Year and Suicidal Behaviors Among Youth

By |2022-07-25T10:15:48-07:00July 25th, 2022|Brief Bulletins from the Field, We Know Psychiatry|

Suicidal behaviors were higher during the school year (average of 6,761/month) compared to school break (average of 4,512/month). Prevalence of suicidal behaviors was highest in October for both hospitalization and primary diagnosis of mood disorder. Among the school year cohort, the rate of suicidal behaviors was higher in youth with [...]

Title

Go to Top